Treatment Approach for Pulmonary Tuberculosis with Chronic Pulmonary Aspergillosis

Diagnosis and Treatment

For patients with concurrent pulmonary tuberculosis and chronic pulmonary aspergillosis, a combination of standard anti-tuberculosis therapy plus oral triazole antifungal therapy is strongly recommended, with voriconazole or itraconazole being the preferred antifungal agents, as recommended by the Infectious Diseases Society of America 1, 2
Chronic pulmonary aspergillosis diagnosis requires 3+ months of chronic pulmonary symptoms or progressive radiographic abnormalities with cavitation, pleural thickening, or pericavitary infiltrates; elevated Aspergillus IgG antibody or other microbiological evidence; and minimal immunocompromise with underlying pulmonary disorders, according to the European Respiratory Society 1
Aspergillus IgG antibody testing is the most sensitive microbiological test for CPA diagnosis, with a strong recommendation and high-quality evidence from the Infectious Diseases Society of America 1
Oral triazole therapy is recommended for progressive and/or symptomatic CPA, with voriconazole and itraconazole being first-line options, as recommended by the European Respiratory Society 2
The duration of antifungal therapy should be at least 4-6 months initially, with extension to 9 months if minimal response is observed, and long-term or indefinite suppressive therapy may be required for chronic cavitary pulmonary aspergillosis, as recommended by the Infectious Diseases Society of America and the European Respiratory Society 1, 2

Hemoptysis management includes oral tranexamic acid for mild-moderate hemoptysis, and bronchial artery embolization for severe hemoptysis, with a strong recommendation and moderate-quality evidence from the Infectious Diseases Society of America 1
Surgical resection may be considered for localized disease with persistent hemoptysis despite other measures, as recommended by the Infectious Diseases Society of America 1

Drug interactions between rifampicin and triazole antifungals require dose adjustments and careful monitoring, with therapeutic drug monitoring essential when using triazoles with rifampicin, as recommended by the European Respiratory Society 2
Patients with minimal response to first-line triazole therapy or developing resistance should be considered for intravenous options or surgical resection, as recommended by the Infectious Diseases Society of America 1

Regular clinical assessment of symptoms and radiographic follow-up are essential, with monitoring of liver function tests and serum triazole levels, as recommended by the European Respiratory Society and the Infectious Diseases Society of America 2, 4
Visual acuity and color discrimination testing should be performed for patients on ethambutol and/or voriconazole, as recommended by the Infectious Diseases Society of America 1